The Journal of Heart and Lung Transplantation
International Society for Heart and Lung Transplantation.

Resolution of post-lung transplant ischemia-reperfusion injury is modulated via Resolvin D1-FPR2 and Maresin 1-LGR6 signaling

Published:December 21, 2022DOI:


      Dysregulation of inflammation-resolution pathways leads to postlung transplant (LTx) ischemia-reperfusion (IR) injury and allograft dysfunction. Our hypothesis is that combined treatment with specialized pro-resolving lipid mediators, that is, Resolvin D1 (RvD1) and Maresin-1 (MaR1), enhances inflammation-resolution of lung IR injury.


      Expression of RvD1 and MaR1 was analyzed in bronchoalveolar lavage (BAL) fluid of patients on days 0, 1, and 7 post-LTx. Lung IR injury was evaluated in C57BL/6 (WT), FPR2−/−, and LGR6 siRNA treated mice using a hilar-ligation model with or without administration with RvD1 and/or MaR1. A donation after circulatory death and murine orthotopic lung transplantation model was used to evaluate the protection by RvD1 and MaR1 against lung IR injury. In vitro studies analyzed alveolar macrophages and type II epithelial cell activation after treatment with RvD1 or MaR1.


      RvD1 and MaR1 expressions in BAL from post-LTx patients was significantly increased on day 7 compared to days 0 and 1. Concomitant RvD1 and MaR1 treatment significantly mitigated early pulmonary inflammation and lung IR injury in WT mice, which was regulated via FPR2 and LGR6 receptors. In the murine orthotopic donation after cardiac death LTx model, RvD1 and MaR1 treatments significantly attenuated lung IR injury and increased PaO2 levels compared to saline-treated controls. Mechanistically, RvD1/FPR2 signaling on alveolar macrophages attenuated HMGB1 and TNF-α secretion and upregulated uptake of macrophage-dependent apoptotic neutrophils (efferocytosis), whereas MaR1/LGR6 signaling mitigated CXCL1 secretion by epithelial cells.


      Bioactive proresolving lipid mediator-dependent signaling that is, RvD1/FPR2 and MaR1/LGR6- offers a novel therapeutic strategy in post-LTx injury.



      SPMs (Specialized pro-resolving lipid mediators), RvD1 (Resolvin D1), MaR1 (Maresin 1), FPR2 (Formyl peptide receptor 2), LGR6 (Leucine-rich repeat containing G-protein coupled receptor 6.)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal of Heart and Lung Transplantation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Valapour M
        • Lehr CJ
        • Skeans MA
        • et al.
        OPTN/SRTR 2019 Annual Data Report: lung.
        Am J Transplant. 2021; 21: 441-520
        • King RC
        • Binns OA
        • Rodriguez F
        • et al.
        Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.
        Ann Thorac Surg. 2000; 69: 1681-1685
        • Laubach VE
        • Sharma AK
        Mechanisms of lung ischemia-reperfusion injury.
        Current Opin Organ Transplantation. 2016; 21: 246-252
        • Yang Z
        • Sharma AK
        • Marshall M
        • Kron IL
        • Laubach VE
        NADPH oxidase in bone marrow-derived cells mediates pulmonary ischemia-reperfusion injury.
        Am j respiratory cell and molecular biol. 2009; 40: 375-381
        • Bharat A
        • Kuo E
        • Steward N
        • et al.
        Immunological link between primary graft dysfunction and chronic lung allograft rejection.
        Ann Thorac Surg. 2008; 86 (discussion 96-7): 189-195
        • Lee JC
        • Christie JD
        Primary graft dysfunction.
        Clin in Chest Med. 2011; 32: 279-293
        • Serhan CN
        Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.
        Annual Rev Immunol. 2007; 25: 101-137
        • Serhan CN
        Pro-resolving lipid mediators are leads for resolution physiology.
        Nature. 2014; 510: 92-101
        • Basil MC
        • Levy BD
        Specialized pro-resolving mediators: endogenous regulators of infection and inflammation.
        Natr Rev Immunol. 2016; 16: 51-67
        • Serhan CN
        • Yang R
        • Martinod K
        • et al.
        Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.
        J Exp Med. 2009; 206: 15-23
        • Serhan CN
        • Clish CB
        • Brannon J
        • Colgan SP
        • Chiang N
        • Gronert K
        Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.
        J Exp Med. 2000; 192: 1197-1204
        • Serhan CN
        • Hong S
        • Gronert K
        • et al.
        Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals.
        J Exp Med. 2002; 196: 1025-1037
        • Chiang N
        • Libreros S
        • Norris PC
        • de la Rosa X
        • Serhan CN
        Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions.
        J Clin Investigation. 2019; 129: 5294-5311
        • Hsiao HM
        • Thatcher TH
        • Colas RA
        • Serhan CN
        • Phipps RP
        • Sime PJ
        Resolvin D1 reduces emphysema and chronic inflammation.
        Am J Pathol. 2015; 185: 3189-3201
        • Jin S
        • Chen H
        • Li Y
        • et al.
        Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21.
        Ann Rheumatic Dis. 2018; 77: 1644
        • Krishnamoorthy S
        • Recchiuti A
        • Chiang N
        • et al.
        Resolvin D1 binds human phagocytes with evidence for proresolving receptors.
        Proc Natl Acad Sci U S A. 2010; 107: 1660-1665
        • Nordgren TM
        • Bauer CD
        • Heires AJ
        • et al.
        Maresin-1 reduces airway inflammation associated with acute and repetitive exposures to organic dust.
        Transl Res. 2015; 166: 57-69
        • Sun Q
        • Wu Y
        • Zhao F
        • Wang J
        Maresin 1 ameliorates lung ischemia/reperfusion injury by suppressing oxidative stress via activation of the Nrf-2-Mediated HO-1 signaling pathway.
        Oxid Med Cell Longev. 2017; 20179634803
        • Oda H
        • Tanaka S
        • Shinohara M
        • et al.
        Specialized proresolving lipid meditators agonistic to formyl peptide receptor Type 2 attenuate ischemia-reperfusion injury in rat lung.
        Transplantation. 2022; 106: 1159-1169
        • Zhao Q
        • Wu J
        • Lin Z
        • et al.
        Resolvin D1 Alleviates the lung ischemia reperfusion injury via complement, immunoglobulin, TLR4, and inflammatory factors in rats.
        Inflammation. 2016; 39: 1319-1333
        • Cai J
        • Gehrau R
        • Tu Z
        • et al.
        MicroRNA-206 antagomiRenriched extracellular vesicles attenuate lung ischemiareperfusion injury through CXCL1 regulation in alveolar epithelial cells.
        J Heart Lung Transplant. 2020; 39: 1476-1490
        • Sharma AK
        • LaPar DJ
        • Stone ML
        • Zhao Y
        • Kron IL
        • Laubach VE
        Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury.
        Am J Transplant. 2013; 13: 2255-2267
        • Sharma AK
        • LaPar DJ
        • Stone ML
        • et al.
        NOX2 activation of natural killer T cells is blocked by the adenosine A2A receptor to inhibit lung ischemia-reperfusion injury.
        Am J Respir Crit Care Med. 2016; 193: 988-999
        • Sharma AK
        • LaPar DJ
        • Zhao Y
        • et al.
        Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury.
        Am J Respir Crit Care Med. 2011; 183: 1539-1549
        • Cheng Q
        • Patel K
        • Lei B
        • et al.
        Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant.
        Am J Transplant. 2018; 18: 2417-2428
        • Sharma AK
        • Fernandez LG
        • Awad AS
        • Kron IL
        • Laubach VE
        Proinflammatory response of alveolar epithelial cells is enhanced by alveolar macrophage-produced TNF-alpha during pulmonary ischemia-reperfusion injury.
        Am J Physiol Lung Cell Mol Physiol. 2007; 293: L105-L113
        • Sharma AK
        • Mulloy DP
        • Le LT
        • Laubach VE
        NADPH oxidase mediates synergistic effects of IL-17 and TNF-α on CXCL1 expression by epithelial cells after lung ischemia-reperfusion.
        Am J Physiol Lung Cell Mol Physiol. 2014; 306: L69-L79
        • Caldarone L
        • Mariscal A
        • Sage A
        • et al.
        Neutrophil extracellular traps in ex vivo lung perfusion perfusate predict the clinical outcome of lung transplant recipients.
        Eur Respir J. 2019; 531801736
        • Sayah DM
        • Mallavia B
        • Liu F
        • et al.
        Neutrophil extracellular traps are pathogenic in primary graft dysfunction after lung transplantation.
        Am J Respir Crit Care Med. 2015; 191: 455-463
        • Zhao M
        • Fernandez LG
        • Doctor A
        • et al.
        Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury.
        Am J Physiol Lung Cell Mol Physiol. 2006; 291: L1018-L1026
        • Pope NH
        • Salmon M
        • Davis JP
        • et al.
        D-series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization.
        The FASEB Journal. 2016; 30: 4192-4201
        • Cai B
        • Thorp EB
        • Doran AC
        • et al.
        MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation.
        Proc Natl Acad Sci U S A. 2016; 113: 6526-6531
        • Rymut N
        • Heinz J
        • Sadhu S
        • et al.
        Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage.
        FASEB J. 2020; 34: 597-609
        • Cai B
        • Kasikara C
        • Doran AC
        • Ramakrishnan R
        • Birge RB
        • Tabas I
        MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity.
        Sci Signal. 2018; 11
        • Wang B
        • Hu C
        • Mei Y
        • et al.
        Resolvin D1 resolve inflammation in experimental acute pancreatitis by restoring autophagic flux.
        Dig Dis Sci. 2018; 63: 3359-3366
        • Yin P
        • Wang X
        • Wang S
        • Wei Y
        • Feng J
        • Zhu M
        Maresin 1 Improves Cognitive Decline and Ameliorates Inflammation in a Mouse Model of Alzheimer's Disease.
        Front Cell Neurosci. 2019; 13: 466
        • Shan K
        • Feng N
        • Cui J
        • et al.
        Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization.
        J Cell Mol Med. 2020; 24: 8045-8056
        • Wang Q
        • Zheng X
        • Cheng Y
        • et al.
        Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na,K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury.
        J Immunol. 2014; 192: 3765-3777
        • Zhang JL
        • Zhuo XJ
        • Lin J
        • et al.
        Maresin1 stimulates alveolar fluid clearance through the alveolar epithelial sodium channel Na,K-ATPase via the ALX/PI3K/Nedd4-2 pathway.
        Lab Invest. 2017; 97: 543-554
        • Zhang H-W
        • Wang Q
        • Mei H-X
        • et al.
        RvD1 ameliorates LPS-induced acute lung injury via the suppression of neutrophil infiltration by reducing CXCL2 expression and release from resident alveolar macrophages.
        Int Immunopharmacol. 2019; 76105877
        • Planaguma A
        • Domenech T
        • Jover I
        • et al.
        Lack of activity of 15-epi-lipoxin A(4) on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function.
        Clin Exp Immunol. 2013; 173: 298-309
        • Tylek K
        • Trojan E
        • Regulska M
        • Lacivita E
        • Leopoldo M
        • Basta-Kaim A
        Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology.
        Pharmacol Rep. 2021; 73: 1004-1019
        • Cattaneo F
        • Parisi M
        • Ammendola R
        Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists.
        Int J Mol Sci. 2013; 14: 7193-7230